

Omentin and apelin concentrations in relation to obesity, diabetes mellitus type two, and cardiovascular diseases in Egyptian population

Atif E. Abd-Elbaky¹ · Dina M. Abo-ElMatty² · Noha M. Mesbah² · Sherine M. Ibrahim³

Received: 29 March 2015 / Accepted: 2 June 2015 / Published online: 16 June 2015
© Research Society for Study of Diabetes in India 2015

Abstract Dysregulation of omentin, a beneficial adipokine, and apelin, an inflammatory adipokine, is thought to play a role in the development of type 2 diabetes mellitus and cardiovascular disease. The objective of this study was to evaluate the relationship between circulating omentin and apelin concentrations and components of the metabolic syndrome in adults with and without type 2 diabetes mellitus or cardiovascular disease. A total of 240 adults, sex- and age-matched, were included in the current case–control study, including 80 healthy, non-obese controls, 80 obese patients with T2DM without cardiovascular disease, and 80 obese patients with T2DM with cardiovascular disease. A fasting blood sample was collected to determine biochemical indicators and insulin resistance index (HOMA-IR). Omentin, apelin, interleukin-1 β (IL-1 β), troponin-T, and oxidized LDL (Ox-LDL) plasma level was assessed by ELISA. Associations of adipokines with biochemical parameters of the patients were determined. Serum omentin levels were significantly lower and serum apelin and IL-1 β concentrations were significantly higher in obese diabetic groups compared to non-obese controls. In correlation analyses, omentin negatively associated with the HOMA-IR index, apelin, and troponin-T, whereas apelin

was positively associated with IL-1 β , BMI, and troponin-T. Our study supports the hypothesis that abnormal production of omentin and apelin can contribute to the pathogenesis of obesity-related complications including T2DM and cardiovascular disease.

Keywords Cardiovascular disease · Omentin · Apelin · IL-1 β · Troponin-T · Ox-LDL · Obesity · Type 2 diabetes mellitus

Introduction

Obesity is a chronic multifactorial disease that is associated with numerous metabolic disorders, including type 2 diabetes mellitus (T2DM) [1, 2]. The major link between obesity and T2DM is insulin resistance (IR). Adipose tissue depots are the most vulnerable target to mediate significant immune cell infiltration and inflammation contributing to systemic inflammation and IR in obese humans [3].

Diabetes has become an epidemic and remains a major public health issue. In 2010, it was estimated that 4.787 million Egyptians (10.4 % of the Egyptian population) had diabetes and that diabetes will increase to 8.615 million Egyptians by the year 2030 [4]. Diabetes mellitus increases the incidence of coronary heart disease, being the most common and clinically important complication in DM [5].

Adipose tissue represents an active endocrine organ by releasing the large number of bioactive mediators (adipokines) that plays an important role in modulating glucose metabolism and inflammation [6]. The adipokine secretion pattern reflects adipose tissue function and seems to be important for determining the individual risk to develop metabolic and cardiovascular comorbidities of obesity [7]. When adipose tissue inflammation and dysfunction have developed,

✉ Sherine M. Ibrahim
catshery@yahoo.com

Dina M. Abo-ElMatty
dinawahadan@yahoo.com

¹ Biochemistry Department, Faculty of Pharmacy, Port Said University, Port Said, Egypt

² Biochemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt

³ Biochemistry Department, Faculty of Pharmacy, Modern Sciences and Arts University, Cairo, Egypt

adipokine secretion is significantly changed towards a diabetogenic, pro-inflammatory, and atherogenic pattern [8].

Omentin, apelin, and IL-1 β are adipokines that play a key role in the cardiovascular disease (CVD) pathophysiology [9]. Omentin is a newly identified secretory protein that is relative to subcutaneous adipose tissue and is highly and selectively expressed in visceral adipose tissue. Low omentin expression was observed in obesity, IR, and T2DM [10]. It was shown that omentin levels correlate inversely with troponin-T and total cholesterol in obese patients with heart disease. Recent studies underscore an anti-inflammatory, anti-atherogenic, and anti-diabetic properties of omentin [11].

The other newly discovered adipokine, apelin-12, is a novel 12-amino peptide expressed in adipocytes of humans; it is encoded by the APLN gene [12]. The synthesis of apelin in adipocytes is triggered by insulin and its plasma levels are reported to increase in association with insulin resistance, hyperinsulinemia, and diabetes mellitus [13]. Our previous studies indicated that in T2DM patients, with or without CVD, the concentration of apelin was significantly increased [14] and positively correlated with concentration of pro-inflammatory cytokine, IL-1 β , as well as negatively correlated with triacylglycerol (TAG) and BMI [15]. Apelin was up-regulated in the atherosclerotic coronary artery, and this peptide localized to the plaque with markers for macrophages and smooth muscle cells [16].

Epidemiological studies showed that IL-1 β as a pro-inflammatory cytokine was significantly increased and correlated with troponin-T and Ox-LDL in obese diabetic patients [17]. IL-1 β has been reported to contribute to β -cell failure and has also been implicated in the progression of atherosclerosis and heart failure [18]. The present work aimed to study the association between novel adipokines and obesity and its diabetic and cardiovascular complications in Egyptian population.

Subjects and methods

Study design

A total of 240 Egyptian adult men were included in this case-control study. Subjects were selected according to our defined inclusion criterion, which was age 35–45 years. Eighty served as healthy, non-obese controls. Patients enrolled in the study were classified into the following groups: 80 type 2 diabetic obese subjects without CVD (T2DM group) selected from patients attending the Endocrinology Department of Suez Canal University hospitals and 80 type 2 diabetic obese subjects with CVD (T2DM+CVD group) admitted to the Intensive Care Unit–Cardiology Department. A patient was considered to have CVD if he had a history of myocardial infarction or the diagnosis was based on the result of coronary

angiography. Exclusion criteria were defined as having the history of any condition that affects inflammatory markers such as known thyroid diseases, malignancies, current smoking, acute or chronic infections, acute or chronic inflammatory disease, hepatic or renal diseases, and alcohol or drug abuse. We limited our study to nonsmokers. The study was approved by the Committee on Medical Ethics of Suez Canal University. The study was carried out in accordance with the regulations and recommendations of the Declaration of Helsinki. All subjects gave their written informed consent prior to participation. A detailed medical history and drug treatment(s) were collected for all subjects. Body mass index (BMI) of all subjects was calculated as weight (kg)/height (m²) and subjects with a BMI equal or more than 30 kg/m² were considered as obese subjects and placed in the obese diabetic group. The control group was those with a BMI lower than 30 kg/m².

Biochemical assay

Participants were weighed in a gown and without shoes. Blood pressure was measured with an automated monitor two times over a 5-min rest period, and the average of the two blood pressures was used in study analyses. The peripheral blood samples were obtained following 10–12 h overnight fasting. Serum was separated, aliquoted, and stored at -80°C . All samples were analyzed by means of a single assay. Standard enzymatic techniques were used for the measurement of fasting serum glucose (FSG) [19] and lipids [total cholesterol (TC) [20] and TAG [21]]. High-density lipoprotein (HDL) was determined after precipitation of APO lipoprotein B-containing lipoproteins [22]. The reference values for the lipid profile were according to established guidelines [23]. Serum insulin concentrations were measured by ELISA method (human insulin ELISA kit; Monobind, Inc., USA) with a minimum detectable concentration of 1.76 mIU/mL.

HOMA calculation

Insulin resistance was calculated by homeostasis model assessment (HOMA). The HOMA-IR was calculated according to HOMA-IR equation = [fasting plasma glucose (mg/dL) \times fasting plasma insulin (mIU/mL)]/405 [24].

Cardiovascular marker determination

Troponin-T as well as Ox-LDL was measured in serum aliquots kept frozen at -80°C using an ELISA kit (MyoBioSource, Inc., USA) according to the manufacturer's instructions (R&D Systems, Wiesbaden, Germany).

Adipokine determination

Inflammatory cytokine, serum IL-1 β , was measured by ELISA kit (Boaster Biological Technology, Inc., USA) with a sensitivity of 6.5 pg/mL [25]. As for novel adipokines, serum omentin levels were measured by ELISA kit (Alpco Diagnostics, Inc., USA) with a sensitivity of 0.4 ng/mL [26]. Serum apelin-12 levels were measured by ELISA kit (MyoBioSource, Inc., USA). The sensitivity of the assay was 0.2 ng/mL and the inter-assay error was below 5 % [27].

Statistical analysis

The data are presented as mean \pm standard deviation (SD). Differences between variables were calculated using Student's *t* test. To determine differences between groups, analysis of variance (ANOVA) was used for multiple comparisons between different groups. Pearson's correlations were computed to assess the relationship between variables. All statistical analyses were performed with SPSS, version 17.0 (SPSS Inc.). *P* values less than 0.05 were considered to be statistically significant.

A multiple linear regression analysis was performed to investigate the independent association between serum apelin and omentin levels (dependent variable) and selected variables that had *P* values <0.05 in univariate analysis (sex and age were also included). *P* values <0.05 were considered statistically significant with a confidence interval of 95 %

Results

A total of 240 subjects were included in this study, and their clinical characteristics are given in Table 1. Compared to controls, patients had significantly changed all conventional risk factors for obesity complications, including BMI, hypertension (defined as a systolic blood pressure (BP) >140 mmHg, a diastolic BP >90 mmHg, or both), FSG, insulin, HDL, TAG, and TC (*P*<0.05). In diabetic groups, a significantly higher serum FSG and insulin levels as well as the HOMA-IR values were observed. In addition, there were no significant differences in the baseline characteristics between diabetic patients and controls in terms of age and sex. Regarding cardiovascular markers in Table 2, there was a significant increase in troponin-T levels in the T2DM group (0.69 \pm 0.05 ng/mL) and T2DM+CVD group (4.71 \pm 1.02 ng/mL) compared with the control group (0.008 \pm 0.01 ng/mL). The Ox-LDL levels were increased 2.9-fold in the diabetic groups compared to controls (*P*<0.05). The T2DM+CVD group also showed significantly higher serum troponin-T and Ox-LDL levels compared to the T2DM group (*P*<0.05). Regarding serum adipokine levels in Table 2, IL-1 β concentrations were

increased in the T2DM and T2DM+CVD groups compared to the control group (28.8 \pm 2.34 and 29.7 \pm 2.1 pg/mL vs. 19.17 \pm 1.76 pg/mL, respectively; *P*<0.05). For omentin, there was a significant decrease in its serum levels in both T2DM and T2DM+CVD groups compared to controls (23 \pm 4.9 and 20.49 \pm 5.4 pg/mL vs. 58.8 \pm 8 pg/mL, respectively; *P*<0.05). Regarding apelin, its serum levels were increased 2.5-fold in the T2DM+CVD group compared to controls (*P*<0.05).

In Pearson's correlation analyses, omentin levels were negatively correlated with insulin (*r*=−0.92, *P*=0.001) in Table 3, HOMA-IR (*r*=−0.89, *P*=0.001), troponin-T (*r*=−0.6, *P*=0.0001), and TC levels (*r*=−0.87, *P*=0.0001) in Fig. 1. However, apelin levels were negatively correlated with omentin (*r*=−0.82, *P*=0.001) in Fig. 2 and positively with IL-1 β (*r*=0.8, *P*=0.001) in Fig. 3, troponin-T (*r*=0.86, *P*=0.001), BMI (*r*=0.84, *P*=0.0001), and TAG (*r*=0.83, *P*=0.0001).

Multiple regression analysis with all the significant variables confirmed that BMI, TAG, troponin-T, and IL-1 β were all determinants of serum apelin levels independently of age, FSG, insulin, and TC in Table 3, while serum omentin levels were dependent on insulin, TC, and troponin-T as well as independent from age, BMI, FSG, and IL-1 β .

Discussion

Obesity is a chronic pathological condition and a risk factor for metabolic syndrome development, T2DM, and CVD [28]. Several studies have shown that visceral obesity is strongly associated with IR, hyperglycemia, dyslipidemia, and hypertension [29]. Moreover, DM is one of the most common chronic diseases in nearly all countries; it is estimated that Egypt will be listed in the top ten countries with the highest numbers of people with diabetes in 2030, reflecting anticipated changes in the population size and structure in Egypt [4].

Type 2 diabetes mellitus and its associated complications have become a public health problem of considerable magnitude. CVD causes most of the excess morbidity and mortality in DM [30]. The cardiovascular risk factors hypertension, dyslipidemia, obesity, IR, and hyperinsulinemia cluster in the metabolic syndrome [31]. All of these mentioned factors, being observed well in the current study, create a state of constant and progressive damage to the vascular wall (increased troponin-T and Ox-LDL), manifested by a low-grade inflammatory process (increased IL-1 β).

Oxidative stress and the oxidation of low-density lipoprotein (LDL) play a role in atherosclerosis and associated risk factors [32]. It is worthy to state that Ox-LDL was significantly increased in the diabetic groups as compared to the control ones in our study. Our results revealed that troponin-T and Ox-LDL were significantly higher in the T2DM+CVD group as compared to the T2DM and control groups. This was also in

Table 1 General characteristics of the study population

Groups <i>n</i>	Control 80	T2DM 80	T2DM+CVD 80	<i>P</i> value
Age (years)	38.6±4.2	42±3	40.3±2.5	NS
BMI (kg/m ²)	21±1.7	32.4±1.4a	32.6±1.6a	0.01
DM duration (years)	–	3.5±1	4.2±0.8	
Systolic blood pressure (mmHg)	114±10.5	133±16.9a	182.6±12.3ab	0.01
Diastolic blood pressure (mmHg)	73.4±4.9	85.2±8.8a	94.7±10.6ab	0.01
FSG (mg/dL)	100±3.7	180±24.6a	182±21.9a	0.01
Insulin (μIU/mL)	7.6±1.3	17.7±3.2a	18.12±3a	0.01
HOMA-IR index	1.9±0.3	11±1.55a	11.07±1.8a	0.01
TAG (mg/dL)	129±29	280±19a	284±20.4a	0.01
TC (mg/dL)	172±16	285±32a	290±23a	0.01
HDL (mg/dL)	38±1.7	25.6±2a	27.4±2.1a	0.01

Data are given as mean±SD, range. Different letters indicate significant difference from control and T2DM without CVD groups, respectively. *P* values are for the comparison between the control and the study groups. *T2DM* type 2 diabetes mellitus without cardiovascular diseases, *T2DM+CVD* type 2 diabetes mellitus with cardiovascular diseases, *BMI* body mass index, *FSG* fasting serum glucose, *TAG* triacylglycerol, *TC* total cholesterol, *HDL* high density lipoprotein, *NS* not significant

support of a previous study [33] where it has been stated that there is a strong, clear association between cardiovascular abnormalities and troponin-T level.

We sought to test the usefulness of IL-1β in our population of diabetic patients. A recent study [15] has described a positive association between IL-1β and obesity, suggesting functional effects on fat mass, fat metabolism, and body mass. This is supported by the positive correlation found between IL-1β and BMI in our study. However, it is known that adipose tissue can synthesize and release the main pro-inflammatory cytokine, IL-1β, which also impairs insulin secretion and induces β-cell apoptosis leading to T2DM [34].

Accumulating evidence indicates that the diseases related to metabolic syndrome are characterized by the abnormal cytokine production, including elevated circulating IL-1β. This was also in support of a previous study [17] where it has been

Table 2 Troponin-T, Ox-LDL, IL-1β, omentin, and apelin in studied groups

Groups <i>n</i>	Control 80	T2DM CVD 80	T2DM+ 80	<i>P</i> value
Troponin-T (ng/mL)	0.008±0.01	0.69±0.05a	4.71±1.02ab	0.01
Ox-LDL (mg/dL)	1.25±0.35	3.1±0.53a	3.73±0.59ab	0.01
IL-1β (pg/mL)	19.2±1.6	28.8±2.3a	29.7±2.1ab	0.01
Omentin (pg/mL)	58.8±8	23±4.9a	20.5±5.4ab	0.01
Apelin (ng/mL)	0.79±0.07	1.79±0.17a	1.99±0.49ab	0.01

Data are presented as mean±SD, range. Different letters indicate significant difference from control and T2DM without CVD groups, respectively. *P* values are for the comparison between the control and the study groups at significance level ≤0.05

IL-1β interleukin-1β, *Ox-LDL* oxidized LDL

shown that IL-1β plays a role in diseases associated with metabolic syndrome such as atherosclerosis and T2DM. In our present study, IL-1β was positively correlated with troponin-T and Ox-LDL in our diabetic groups.

According to a previous study [35], in addition to the effective pro-inflammatory adipokine described above, adipose tissues also secrete a smaller number of anti-inflammatory factors, such as omentin. Omentin is a novel visceral fat

Table 3 Multiple linear regression analysis using either apelin or omentin as dependent variable

Variable	Omentin		Apelin	
	β	<i>P</i>	β	<i>P</i>
Age	−0.235	NS	0.168	NS
BMI	−0.449	NS	0.44	<0.001
D.M duration	−0.148	NS	0.258	NS
FSG	−0.117	NS	0.224	NS
TC	−0.62	0.01	0.183	NS
TAG	−0.18	NS	0.45	<0.001
HDL-C	0.464	NS	−0.229	NS
Insulin	−0.42	0.01	0.689	NS
HOMA-IR	−0.44	0.01	0.69	NS
Troponin-T	−0.66	<0.0001	0.67	<0.0001
Ox-LDL	−0.431	NS	0.51	NS
IL-1β	−0.534	NS	0.46	<0.01
Omentin			−0.64	0.01
Apelin	−0.64	0.01		

Evaluated by multiple linear regression models with several levels of adjustment

β standardized coefficients, *NS* not significant




Fig. 1 Correlation between omentin and total cholesterol (TC) in diabetic patients (groups T2DM and T2DM+CVD) ($n=160$). Each individual value is represented by a filled square. r =Pearson's correlation coefficients

depot-specific adipokine which is considered to be linked to T2DM in various populations. Omentin has been reported to have an association with visceral obesity, IR, and glucose metabolism [36]. In the present study, we demonstrated that circulating levels of omentin were inversely correlated with a number of metabolic risk factors (TC and troponin-T). Individuals in our study with an excess of visceral fat accumulation (diabetic groups) have a high risk of the development of metabolic syndrome in comparison with non-obese control group.

Our results showed that omentin level was significantly reduced in the diabetic patients with and without CVD as compared to the healthy controls. Moreover, the negative correlation of troponin-T with omentin in our diabetic groups is consistent with the study [37] on Chinese patients that showed that low levels of circulating omentin are also associated with the prevalence of coronary artery disease. These data suggest




Fig. 2 Correlation between apelin and omentin in diabetic patients (groups T2DM and T2DM+CVD) ($n=160$). Each individual value is represented by a filled square. r =Pearson's correlation coefficients




Fig. 3 Correlation between apelin and IL-1 β in diabetic patients (groups T2DM and T2DM+CVD) ($n=160$). Each individual value is represented by a filled square. r =Pearson's correlation coefficients

that omentin may represent a biomarker for not only metabolic disorders but also CVD.

In another study [38] on an obese Caucasian population, omentin levels were found to be correlated with some markers of lipid metabolism such as TC which indicates that omentin may play a role in lipid metabolism or diabetic dyslipidemia as a compensatory mechanism; this is consistent with our results which showed a negative significant correlation between omentin levels and TC levels in our obese diabetic groups.

A previous study [39] showed that decreased serum omentin levels observed in obese humans might cause a reduction of insulin-stimulated glucose uptake in visceral and subcutaneous adipocytes or other insulin-sensitive tissues and contributing, at least partially, to insulin resistance, and this was supported in our study by the negative correlation between omentin levels and insulin levels as well as HOMA-IR as an indicator of insulin resistance in our obese diabetic groups (T2DM and T2DM+CVD).

According to a recent study [35], obesity leads to the down-regulation of anti-inflammatory factors, such as omentin, and the up-regulation of IL-1 β and apelin that activate endothelial cells and promote a dysfunctional phenotype. Apelin is another short peptide released from adipocytes originating from a 77-amino-acid precursor and its synthesis is stimulated by insulin.

Collected data from both the clinical and basic research settings showed that apelin correlates with states of IR and obesity and decreases insulin secretion [40]. Recently, studies [41] have disclosed a markedly increased plasma apelin level in obese T2DM subjects; this result was supported by the significant positive correlation between apelin and BMI as an indicator of obesity in our obese diabetic groups (T2DM and T2DM+CVD). The connection between apelin and T2DM has been postulated.

Meanwhile, we also found that apelin was significantly correlated with IL-1 β in our obese diabetic groups. Therefore, we speculated that apelin might be involved in the pathophysiologic process in obese T2DM patients, taking into account the role of IL-1 β in the development of IR and atherosclerosis.

Although apelin has been viewed as a beneficial adipokine up-regulated in obesity as confirmed by a previous study [42], our results revealed that apelin has a positive and negative significant correlation between troponin-T and omentin in our diabetic groups, respectively.

As new adipokines, apelin was likely to be involved in the pathophysiology of T2DM and CVD, and this could be explained by different mechanisms such as the level of apelin in our obese T2DM patients that correlated closely with BMI and the elevated levels that may be a result of IR compensatory reaction. However, as the other side of the coin, apelin may also inhibit the release of insulin, aggravating the disorders of glucose metabolism which was also proved by a previous study [43]. Moreover, by coordinating with other factors associated with increased circulating free fatty acids, apelin may cause the occurrence of IR [44].

Another explanation was shown by another study [45] where it has been reported that apelin correlated with oxidative stress and inflammation markers (Ox-LDL and IL-1 β). As important inflammatory factors, they could be involved in the development of atherosclerosis. Thus, understanding the contribution of such an adipokine in obesity-associated disorders appears to be of major importance.

In conclusion, in the face of the current obesity epidemic, the nature of the relationship between obesity and T2DM is of great importance. However, it seems that in obese patients, such as those suffering from diabetes or CVD, in addition to obesity, the type of illness also affects inflammatory or anti-inflammation mediators' levels. The present study indicates that lower concentrations of circulating omentin together with higher concentrations of apelin are linked with an increase in multiplicity of metabolic risk factors, suggesting that omentin and apelin serve as beneficial biomarkers for assessment of metabolic risk factors.

Acknowledgment We would like to thank Sigma pharmaceuticals for providing reagents at a reduced cost.

Conflicts of interest There are no conflicts of interest.

Funding This research was funded by the Suez Canal University.

Ethical approval The study was approved by the Committee on Medical Ethics of Suez Canal University. The study was carried out in accordance with the regulations and recommendations of the Declaration of Helsinki (REC number GH2008H).

References

1. Suresh S, Mahendra J. Multifactorial relationship of obesity and periodontal disease. *J Clin Diagn Res.* 2014;8:E01–3.
2. Al-husseini N, Arafat N, Mohammed E, Allam M. Effect of exercise training on adiponectin receptor expression and insulin resistance in mice fed a high fat diet. *Am J Biochem Biotechnol.* 2010;6:77–83.
3. Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. *Science.* 2013;339:172–7.
4. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract.* 2010;87:4–14.
5. Horwich T, Fonarow G. Glucose, obesity, metabolic syndrome, and diabetes: relevance to incidence of heart failure. *J Am Coll Cardiol.* 2010;55:283–93.
6. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. *Mol Med.* 2008;14:741–51.
7. Bays HE. Sick fat, metabolic disease and atherosclerosis. *Am J Med.* 2009;122:S26–37.
8. Bluher M. Adipose tissue dysfunction in obesity. *Exp Clin Endocrinol Diabetes.* 2009;117:241–50.
9. Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. *J Endocrinol.* 2013;216:17–36.
10. Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. *Diabetes Res Clin Pract.* 2010;88:29–33.
11. Zhou JY, Chan L, Zhou SW. Omentin: linking metabolic syndrome and cardiovascular disease 2014; 12: 136–143.
12. Castan-Laurell I, Dray C, Knauf C, Kunduzova O, Valet P. Apelin, a promising target for type 2 diabetes treatment. *Trends Endocrinol Metab.* 2012;23:234–41.
13. Erdem G, Dogru T, Tasci I, Sonmez A, Tapan S. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. *Exp Clin Endocrinol Diabetes.* 2008;116:289–92.
14. Machura E, Szczepanska M, Ziora K, Ziora D, Swietochowska E. Evaluation of adipokines: apelin, visfatin, and resistin in children with atopic dermatitis. *Mediat Inflamm.* 2013;2013:119–27.
15. Manica-Cattani MF, Bittencourt L, Rocha MI, Algarve TD, Bodanese LC, Rech R. Association between interleukin-1 beta polymorphism and obesity. *Mol Cell Endocrinol.* 2010;314:84–9.
16. Pitkin SL. Modulation of the apelin system in heart failure and atherosclerosis in human. *Br J Pharmacol.* 2010;160:1785–95.
17. Mojtaba E, Shahram S, Heshmatolah P, Alireza Z. Pro-inflammatory cytokine interleukin-1 beta is associated with cardiovascular fitness in sedentary diabetic patients. *J Biodivers Environ Sci.* 2011;1:37–44.
18. Zhao G, Dharmadhikari G, Maedler K, Meyer-Hermann M. Possible role of interleukin-1 β in type 2 diabetes onset and implications for anti-inflammatory therapy strategies. *PLoS Comput Biol.* 2014;10:100–8.
19. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. *J Clin Pathol.* 1969;22:158–61.
20. Richmond W. Preparation and properties of a cholesterol oxidase from *Nocardia* sp. and its application to the enzymatic assay of total cholesterol in serum. *Clin Chem.* 1973;19:1350–6.
21. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. *Clin Chem.* 1983;29:1075–80.
22. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. *J Lipid Res.* 1970;11:583–95.

23. Hatch FT, Lees RS. Practical methods for plasma lipoprotein analysis. *Adv Lipid Res.* 1968;6:1–68.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Teacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β cell function from fasting plasma glucose and insulin concentration in man. *Diabetologia.* 1985;28:412–9.
25. Chen CN, Li YSJ, Yeh YT, Lee PL. Synergistic roles of platelet-derived growth factor-BB and interleukin-1- β in phenotypic modulation of human aortic smooth muscle cells. *Proc Nat Acad Sci.* 2006;103:2665–70.
26. Tan BK, Adya R, Farhatullah S, Lewandowski KC, O'Hare P, Lehnert H, et al. Omentin-1, a novel adipokine, is decreased in overweight insulin resistant women with the polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. *Diabetes.* 2008;57:801–8.
27. Principe A, Melgar-Lesmes P, Fernández-Varo G, Del Arbol LR, Ros J, Bernardi M, et al. The hepatic apelin system: a new therapeutic target for liver disease. *Hepatology.* 2008;48:1193–201.
28. Mirzaei K, Hossein-Nezhad A, Aslani S, Emamgholipour S, Karimi M, et al. Energy expenditure regulation via macrophage migration inhibitory factor (MIF) in obesity and in vitro anti-MIF effect of *Alpinia officinarum* Hance extraction. *Endocr Pract.* 2011;18:39–48.
29. Van RE, Jankowski CM, Gozansky WS, Schwartz RS, Kohrt WM. Lower-body adiposity and metabolic protection in postmenopausal women. *J Clin Endocrinol Metab.* 2005;90:4573–8.
30. Casper G, Coen DA. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. *Clin Sci.* 2005;109:143–59.
31. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. *Obes Res.* 2003;11:1278–89.
32. Arthur S, Ulf G. Dyslipidemia and risk of coronary heart disease: role of lifestyle approaches for its management. *Am J Life Style Med.* 2009;3:257–73.
33. Defilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. *JAMA.* 2010;304:2494–502.
34. DeNardo D, Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. *Trends Immunol.* 2011;32:373–9.
35. Ohashi K, Shibata R, Murohara T, Ouchi N. Role of anti-inflammatory adipokines in obesity related diseases. *Trends Endocrinol Metab.* 2014;25:348–55.
36. Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, et al. Circulating omentin is associated with coronary artery disease in men. *Atherosclerosis.* 2011;219:811–4.
37. Zhong X, Zhang HY, Tan H, Zhou Y, Liu FL, et al. Association of serum omentin-1 levels with coronary artery disease. *Acta Pharmacol Sin.* 2011;32:873–8.
38. Moreno-Navarrete JM, Catalan V, Ortega F, Gomez-Ambrosi J, Ricart W. Circulating omentin concentration increases after weight loss. *Nutr Metab.* 2010;7:27–38.
39. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, et al. Identification of omentin as a novel depot specific adipokine in human adipose tissue: possible role in modulating insulin action. *Am J Physiol Endocrinol Metab.* 2006;290:1253–61.
40. Soriguer F, Garrido-Sanchez L, Garcia-Serrano S, Garcia-Almeida JM, Garcia-Arnes J. Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus. *Obes Surg.* 2009;19:1574–80.
41. Dray C, Debard C, Jager J, Disse E, Daviaud D, Martin P, et al. Apelin and APJ regulation in adipose tissue and skeletal muscle of type 2 diabetic mice and humans. *Am J Physiol Endocrinol Metab.* 2010;298:1161–9.
42. Higuchi K, Masaki T, Gotoh K, Chiba S, Katsuragi I, Tanaka K, et al. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. *Endocrinology.* 2007;148:2690–7.
43. Beltowski J. Apelin and visfatin: unique “beneficial” adipokines up-regulated in obesity. *Med Sci Monit.* 2006;12:112–9.
44. Attane C, Daviaud D, Dray C. Apelin stimulates glucose uptake but not lipolysis in human adipose tissue ex vivo. *J Mol Endocrinol.* 2011;46:21–8.
45. Garcia-Diaz D, Campion J, Milagro FI, Martinez JA. Adiposity dependent apelin gene expression: relationships with oxidative and inflammation markers. *Mol Cell Biochem.* 2007;305:87–94.